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ABSTRACT
Diabetes mellitus (DM) is caused by abnormal insulin secretion, impaired 
insulin action, or both. Approximately 12-25% of type 2 diabetes mellitus 
(T2DM) patients will develop diabetic foot ulcers (DFU). Vascular endothelial 
growth factor (VEGF) is a group of platelet-derived growth factors (PDGF) 
which have a potential role in angiogenesis. Low levels of VEGF-A can cause 
insufficient angiogenesis leading to wound healing inhibition. The 2578*C/A 
polymorphism of VEGF-A gene has been reported as a candidate marker 
for the DFU development. However, the variant role in the development of 
DFU in Javanese ethnic needs to be clarified. This study was conducted to 
compare VEGF-A levels and the -2578*C/A polymorphism of the VEGF gene 
among diabetic patients with and without DFU in Javanese ethnic. In this 
case-control study, the T2DM individuals with DFU as case group (n=19) and 
without DFU as control group (n=41) were recruited. The VEGF-A levelswere 
determined by ELISA. The ARMS-PCR technique was applied to investigate the 
presence of -2578*C/A polymorphism of the VEGF gene. Data were analyzed 
with independent t, Mann-Whitney, Chi-square, and Kruskal-Wallis tests with 
significance level of p<0.05. The median of plasma VEGF-A level was significantly 
different between case and control groups (p=0.001). The genotype frequency 
of -2578*C/A polymorphism of VEGF gene was no difference between case and 
control groups. However, individuals with C allele have a higher risk factor to 
develop DFU than A allele (CC+CA vs AA;p=0.042; OR=2.5). The plasma VEGF-A 
levels were lower in T2DM subjects with DFU than those without DFU. In 
conclusion,individuals with C allele of -2578*C/A polymorphism of VEGF gene 
are more susceptible to have DFU than individuals with A allele in Javanese 
ethnic with T2DM.
ABSTRAK
Diabetes mellitus disebabkan gangguan sekresi dan aksi insulin atau keduanya. 
Antara 12-25% pasien diabetes mellitus tipe 2 (DMT2) akan mengalami ulkus 
kaki diabetik (DFU). Vascular endothelial growth factor (VEGF) adalah kelom-
pok platelet-derived growth factors (PDGF) yang punya peran potensial dalam 
angiogenesis. Kadar rendah VEGF-A dapat menyebabkan kurangnya angio-
genesis sehingga menghambat proses penyembuhan. Polimorfisme 2578*C/A 
gen VEGF telah dilaporkan sebagai calon penanda untuk terjadinya DFU. Na-
mun demikian, peranvarian gen dalam berkembangkan DFU pada suku Jawa 
perlu dibuktikan. Penelitian telah dilakukan untuk membandingkan kadar 
VEGF-A dan polimorfisme -2578*C/A gen VEGF pada penderita diabetes suku 
Jawa dengan dan tanpa DFU. Penelitian kasus control ini melibatkan pasien 
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DMT2 dengan DFU sebagai kelompok kasus (n=19) dan tanpa DFU sebagai kon-
trol (n=41). Kadar VEGF-A ditetapkan dengan metode ELISA. Teknik ARMS-PCR 
digunakan untuk mendeteksi adanya polimorfisme -2578*C/A gen VEGF. Data 
dianalisis menggunakan uji t independent, Mann-Whitney, Chi-square dan Krus-
kal-Wallis dengan tingkat kemaknaan p < 0.05. Nilai median kadar VEGF-A plas-
ma berbeda bermakna antara kelompok kasus dan kelompok kontrol (p=0.001). 
Frekuensi genotype polimorfisme -2578*C/A gen VEGF tidak berbeda bermakna 
antara kelompok kasus dan kontrol. Namun demikian, pasien yang membawa 
alel C mempunyai factor risiko lebih tinggi berkembangnya DFU dibandingkan 
yang membawa alel A (CC+CA vs AA; p=0.042; OR=2.5). Kadar VEGF-A plasma 
pasien DMT2 dengan DFU lebih rendah dibandingkan pasien tanpa DFU. Dapat 
disimpulkan, pasien yang membawa alel C -2578*C/A polimorfisme gen VEGF 
lebih rentan terhadap berkembangnya DFU dibandingkan pasien yang memba-
wa alel A pada suku Jawa penderita DM.
INTRODUCTION
Diabetic foot ulcer (DFU) is a common 
infection among patients with diabetes 
mellitus (DM) due to tissue invasion 
accompanied by microorganism’s 
proliferation leading to tissue damage 
with or without an inflammatory 
response of the host cell.1 Approximately 
12-25% of diabetic patients will develop 
DFU.2 While its prevalence is low in 
Western countries, India is the country 
with the highest rate of amputation 
for DFU in Asia. It was reported that 
3.6% of DM patients in India developed 
DFU in 1994.3 In Indonesia, while the 
exact number of DFU is unknown, the 
population of DM patients has been 
increasing and was ranked 7th in the world 
with approximately 10 million cases 
in 2015.4  The diabetes complications 
such as DFU are also predicted to be 
higher with the rising of DM’s annual 
prevalence which subsequently reduces 
the quality of life of patients. Poor 
glycemic and hygienic control of diabetic 
patients play an important role in the 
increasing chance of skin infection and 
the cell’s reduced responsiveness against 
microorganisms.5
Angiogenesis plays an important role 
in the wound healing process. Vascular 
endothelial growth factor-A (also 
referred to as VEGF) is a group of platelet-
derived growth factors (PDGF) which has 
a potential role in angiogenesis.6  Wilgus 
et al.7  reported the important role of 
VEGF-A in wound healing. Increased 
levels of VEGF-A are related to the 
alteration of the scar and the recovery of 
fetus skin fibrosis, also reduction of scars, 
and improved collagen quality. Vascular 
endothelial growth factor improved 
wound healing in diabetic wounds. 
The VEGF alsoinduced chemotaxis and 
angiogenesis. Angiogenesis inhibition 
would inhibit wound healing.7
The -2578*C/A polymorphism of the 
VEGF-A gene is one of the polymorphisms 
located in the 5’untranslated promoter 
region.8 Marsh et al.9 reported that 
this polymorphism reduces mRNA 
expression, which influences the tissue 
wound healing process.10 Amoli et al.11 
investigated -2578*C/A VEGF gene 
variations and found that this variant 
was the candidate risk factor of DFU 
development in an Iranian population. 
Shahbazi et al.12 reported that -2578*C/A 
polymorphism of the VEGF gene leads to 
diminished VEGF level. 
This study was conducted to compare 
plasma VEGF levels and to investigate the 
-2578*C/A polymorphism of the VEGF-A 
gene among diabetic patients with and 
without DFU in a Javanese ethnic.
MATERIALS AND METHODS
Subjects
It was a case-control study. The 
subjects were divided into two groups. 
The case group was T2DM patients with 
DFU, and the control group was T2DM 
patients without DFU. Subjects were 
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recruited from Dr. Sardjito General 
Hospital, Yogyakarta, Indonesia.
The physical examination was 
used to determine the DFU status. The 
Wagner Grading System was performed 
for foot ulcer assessing, and grading. 
The anamneses and family pedigree 
were used to confirm the ethnic status. 
The Javanese men or women aged 30-
65 years old who have been diagnosed 
with T2DM at least 5 years and DFU were 
recruited as the case group. The patients 
with the same previous characteristics 
but without DFU were included as the 
control group. The patient informed 
consent forms were signed by all patients 
which were included in this study. Five 
mL of venous blood was collected in 
EDTA tubes and examined for VEGF-A 
plasma level and genotyping of VEGF-A 
gene. Ethical clearance of this study was 
obtained from the Medical and Health 
Research Ethic Committee, Faculty of 
Medicine Public Health and Nursing, 
Universitas Gadjah Mada, Yogyakarta.
Enzyme-linked immunosorbent assay 
(ELISA)
The plasma VEGF-A levels 
were measured by enzyme-linked 
immunosorbent assay (ELISA) 
using Abcam®Kit according to the 
manufacturer’s instruction. 
DNA Isolation
DNA isolations were carried out using 
Tianamp blood DNA kit (Tiangen®). The 
DNA yields were stored at -20˚C.
Tetra-primer amplification refractory 
mutation system-polymerase chain 
reaction (ARMS-PCR)
The ARMS-PCR technique described 
by Amoli et al.11 was performed to 
determine -2578*C/A polymorphism of 
the VEGF-A gene and used five primers 
(TABLE 1).11 Three types of master 
mix were made based on the type of 
primer; the first reaction of master mix 
contained generic forward primer and 
antisense primer C, the second reaction 
of master mix contained generic forward 
primer and antisense primer A, and the 
third reaction of master mix contained 
the primer of beta actin. Two µL of DNA 
solution was added to the 4.2 µL of master 
mix. As much as 13.8 µL nuclease-free 
water was added to the solution.
Twenty µL of mixtures were 
amplified on the thermocycler (ESCO®). 
The hot-start step was carried out for 10 
min at 95°C. The following 35 cycles of 1 
min for denaturation at 95°C, 1 min for 
annealing at 60°C, 1 min for elongation 
at 72˚C were performed. Final elongation 
was carried out for 7 min at 72˚C. The 
amplicons were electrophoresed in 2% 
of agarose gel and visualized under UV 
illumination. Genotypes were identified 
by the presence or absence of the 
amplified target sequence. The expected 
PCR product was 223 bp for VEGF-A and 
315 bp for beta actin.
TABLE 1. List of primers used in this experiment according to Amoli et al.11
Primer Sequence
Generic forward primer 5’-TTAGGACACCATACCGATGG-3’
C anti- sense primer 5’-TCTGATTATCCACCCAGATCG-3’
A anti- sense primer 5’-TCTGATTATCCACCCAGATCT-3’
Forward (beta actin) 5’-CTTCCTTCCTGGGCATGGAG-3’
Reverse (beta actin) 5’-TGGAGGGGCCGGACTCGTCA-3’
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Statistical analysis
Characteristics of the subjects 
were analyzed by Independent t-test or 
Mann-Whitney test. Genotype and allele 
frequencies were analyzed by the Chi-
square test. The distribution of plasma 
VEGF-A levels in individuals with T2DM 
and without DFU was analyzed by Mann-
Whitney test. The value was considered 
significant if the p-value is less than 0.05.
RESULTS
Clinical characteristic of T2DM 
patients
In this study, the 60 T2DM patients 
were divided into two different groups. 
The 19 patients with DFU were sub-
grouped as the case group, while the 41 
patients without DFU (NDFU) were sub-
grouped as the control group. TABLE 2 
shows data of the clinical characteristics 
of the patients obtained from medical 
records. There was no significant 
difference in clinical characteristics 
between case and control subjects 
(p>0.05).
Plasma VEGF-A level related to 
diabetic foot ulcer incidence
The median of VEGF-A levels in the 
case and control subjects are shown 
in TABLE 3. The VEGF-A level of case 
subjects was significantly lower than 
control subjects (p = 0.001). 
TABLE 2. Clinical characteristics of patients
Variable DFU (n=19) NDFU (n=41) p
Sex
•	 Men 6 (%) 16 (%) 0.581
•	 Women 13 (%) 25 (%)
Age (year) 54.8±6.7 55.8±6.2 0.597
BMI (kg/m2) 22.9 (16.8-24.9) 22.6 (16.1-24.8) 0.709*
Blood pressure (mmHg)
•	 Systole 128.6±20.9 127.4±23.7 0.770#
•	 Diastole 75.5±14.8 77.7±13.1 0.554
Total cholesterol (mg/dL) 202.8±62.9 202.4±40.4 0.824#
Fasting blood glucose (mg/dL) 164.3±54.6 189.1±78.6 0.271#
Data are reported as mean±SD or median (minimum-maximum); *Man-Whitney 
test; #Independent t-test.
TABLE 3. The VEGF-A level of case (DFU) and control (NDFU) groups






Data are reported as median (minimum-maximum); *Mann-Whitney test.
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Genotype and allele frequencies 
distribution of the -2578*C/A 
polymorphism in the VEGF-A gene
Three genotypes were found in the 
control group (CC, CA, and AA), while two 
genotypes were found in the case group 
(CC and CA) (FIGURE 1). The distributions 
of genotypes and alleles were statistically 
analyzed using Chi-square  test (TABLE 
4). Chi-square analysis showed that 
differences of genotype and allele 
frequencies of -2578*C/A VEGF-A in 
the case and control subjects were not 
statistically significant (p = 0.289 for the 
genotype frequencies and p = 0.653 for 
allele frequencies). But the major allele 
(C allele) conferred a risk factor for the 
DFU development (OR = 2.5; p = 0.042).
FIGURE 1. Genotype result of -2578 * C/A VEGF-A gene 
polymorphism. M = marker. B = beta actin. 
CC = wild-type. CA = mutant heterozygote. 
AA = mutant homozygote. Z3=AA, Z29=CC, 
Z21=CA, Z37=CA.
TABLE 4. Distribution of genotype and allele VEGF-A -2578 *C/A in 
case (DFU) and control (Non DFU) subject
Variable DFU (n=19) Non DFU (n=41) p
Genotype 
• AA 0 2 (4.9)
0.289*a• CA 16 (84.2) 27 (65.9)
• CC 3 (15.8) 12 (29.3)
Allele
• A 16 (42.1) 31 (37.8) 0.653*
• C 22 (57.9) 51 (62.2)
• CC + CA 19 29 0.042*a
• AA 0 2
*aChi square test; * Yates correction
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Association between VEGF-A 
plasma level with -2578*C/A VEGF-A 
polymorphism
The relationship of VEGF-A profile 
and VEGF-A polymorphisms are shown 
in TABLE 5. Results showed that VEGF-A 
levels in the AA genotype are higher 
than CC and CA genotypes. However, the 
VEGF-A levels were not significantly dif-
ferent between that genotype groups af-
ter statistical analysis (p= 0.138).
TABLE 5. VEGF-A level in T2DM patients with CC+CA compared to AA genotypes
Variable T2DM (DFU and Non DFU) p
CC + CA AA
VEGF-A level 1120.5 2186.8 0.138*
(pg/mL) (19.5-4908.7) (1709.9-2663.7)
Data are reported as median (minimum-maximum); *Mann-Whitney test
DISCUSSION
This study confirmed that a low 
VEGF-A level leads to poor angiogenesis, 
and is a risk factor for the development 
of DFU. The VEGF-A levels of the control 
group (non-DFU) are significantly higher 
than the case group (DFU) (p= 0.001). In 
previous study, the VEGF-A plasma level 
is associated with the development of 
diabetic retinopathy and nephropathy. 
High levels of VEGF-A are a risk factor 
for diabetic retinopathy. In contrast, our 
results showed that low levels of VEGF-A 
act as a risk factor for DFU. Hoong et al.13 
examined the VEGF-A levels in T2DM and 
found that the levels were higher than 
in healthy subjects. The median VEGF-A 
level of healthy subjects was 90 (10-230) 
pg/mL, whereas the median VEGF-A 
level in theT2DM patients was 180 (120-
420) pg/mL.13 Another study found that 
VEGF-A levels of diabetic patients were 
increased relative to healthy controls 
(928.9±443.2 and 491.7±275.5 pg/mL, 
respectively).14 These results support 
the previous idea that levels of VEGF-A 
should be maintained within normal 
ranges to prevent the progression of 
complications in diabetic patients.
In the aim to investigate the 
association between VEGF polymorphism 
and VEGF level, we genotyped subjects 
for -2578C*/A polymorphism. The results 
showed the presence of three genotypes 
of CC, CA, and AA. Statistical analysis 
revealed that the genotype and allele 
frequencies of -2578*C/A polymorphisms 
of the VEGF-A gene are not significantly 
different between case and control 
subjects (TABLE 4). In addition, the level 
of VEGF-A was compared among each 
genotype to determine the relationship 
of -2578*C/A polymorphisms. The 
VEGF-A levels in AA genotype patients 
are higher than those of CC and CA 
genotype patients, but the difference was 
not significant statistically (p = 0.138). 
This result is similar to Habboubi et al.15 
who also reported that VEGF-A level of 
CC, CA, and AA genotype carriers were 
not significantly different from healthy 
subjects. But this finding is contrary 
to the research that was reported by 
Guerzoni et al.16 who found that VEGF-A 
expression was diminished due to the AA 
genotype at -2578 VEGF-A. Apparently, 
the production of VEGF-A is influenced 
by both genetic and non-genetic 
determinants.17,18 Since many factors 
contribute to the VEGF-A expression, a 
direct association between -2578*C/A 
polymorphism and plasma VEGF-A level 
in patients with T2DM is still in debate.19 
However, when the genotypes are 
divided based on risk alleles, the CA 
and CC groups are more susceptible to 
DFU compared to the AA (OR = 2.5; p = 
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0.042) (TABLE 4). This means that the 
probability of patients who carry CC 
and CA genotypes developing DFU is 
71.4% higher than the AA genotype. 
Since the C allele is a common one, 
many patients with T2DM are actually 
prone to DFU in the Indonesian Javanese 
population. The mechanism by which 
the C allele reduces VEGF-A expression is 
unknown. The -2578*C/A polymorphism 
of the VEGF-A gene is one of the five 
promoter polymorphisms present in 
the 5’untranslated region (UTR), which 
has been identified so far.8 Several 
transcription factors bind to this region 
and polymorphisms located here cause 
alteration of VEGF-A expression. It 
is speculated that one C allele is not 
strong enough to drive low VEGF-A 
production since the interaction of other 
transcription factors may occur.20,21
High blood glucose levels affect the 
circulating of angiogenic factors that 
contribute to the inhibition of wound 
healing. Natarajan et al.22 reported that 
hyperglycemia was a major determinant 
to the elevating of VEGF-A expression. 
Metabolic balance disorders, such as 
diabetes can elevate the oxidation of 
sorbitol to fructose and cause reduction 
of NAD+ to NADH. Once the redox  balance 
is disturbed, it would elevate superoxides 
that induce VEGF production leading to 
endothelial dysfunction.23
Other variables that might be 
considered in the development of DFU 
are proinflammatory mediators which 
increase in patients with T2DM and 
induce inflammation continuously. 
Mild inflammation causes impaired 
cellular defense mechanisms because of 
hyperglycemia. It has been shown that 
there is a strong relationship between 
the development of DFU with proteolytic 
environment.24 Impaired wound healing 
in patients with DM is also caused by 
a reduction of angiogenesis ability. 
Research shows that the number of 
growth factors has decreased in diabetic 
wounds caused by proinflammatory 
mediators.25 The release of VEGF, PDGF, 
and TGF-β from platelets, monocytes, 
and fibroblasts induces angiogenesis 
that is important in the wound healing 
process.26 If these growth-factors were 
reduced, insufficient angiogenesis will 
occur.
Most diabetic patients undergo 
peripheral polyneuropathy, as the most 
common form of diabetic neuropathy.27 
Diabetic neuropathy is another risk 
factor of developing foot ulcers since 
patients will have a loss of sensation 
because of nerve damage.28 VEGF-A 
is not the only factor that affects the 
wound healing of DFU. Pathophysiology 
of DM and impaired wound healing 
are very complex. Diabetic patients 
undergo an abnormal  development 
process of wound healing compared 
with the normal subjects. It is caused 
by the association of diabetes and 
microangiopathy and also their impaired 
immune system.29,30 Therefore, research 
on these topics are very important to 
understand the pathophysiology of 
DFU and to overcome this  problem 
in Indonesia. One limitation of this 
research is the small sample size. We had 
difficulty recruiting samples because 
some patients with DFU had comorbid 
complications with other diseases that 
affect the angiogenesis process.
CONCLUSION
The plasma VEGF-A levels are lower 
in T2DM subjects with DFU than those 
without DFU. Individuals with C allele 
of -2578*C/A polymorphism of the VEGF 
gene are more susceptible to have DFU 
than individuals with A allele in Javanese 
ethnic with T2DM.
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